ST Germain D J Co. Inc. Grows Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

ST Germain D J Co. Inc. increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 12.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,072 shares of the medical equipment provider's stock after purchasing an additional 11,227 shares during the quarter. ST Germain D J Co. Inc. owned approximately 0.05% of Zimmer Biomet worth $11,553,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Dorsey & Whitney Trust CO LLC lifted its position in shares of Zimmer Biomet by 2.3% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock valued at $485,000 after buying an additional 102 shares during the last quarter. M&T Bank Corp lifted its position in Zimmer Biomet by 0.4% during the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock valued at $2,834,000 after acquiring an additional 108 shares during the last quarter. MGO One Seven LLC boosted its stake in Zimmer Biomet by 5.1% in the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock valued at $238,000 after acquiring an additional 110 shares in the last quarter. FWG Holdings LLC boosted its stake in Zimmer Biomet by 3.5% in the fourth quarter. FWG Holdings LLC now owns 3,715 shares of the medical equipment provider's stock valued at $402,000 after acquiring an additional 124 shares in the last quarter. Finally, Erste Asset Management GmbH increased its position in shares of Zimmer Biomet by 0.3% during the fourth quarter. Erste Asset Management GmbH now owns 41,487 shares of the medical equipment provider's stock worth $4,434,000 after purchasing an additional 124 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Shares of ZBH stock traded down $0.30 during mid-day trading on Wednesday, hitting $91.55. 1,528,016 shares of the stock were exchanged, compared to its average volume of 1,797,393. The firm has a fifty day moving average of $99.19 and a 200 day moving average of $104.50. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.71. The company has a market cap of $18.11 billion, a PE ratio of 20.57, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company's revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.94 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.05%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group reduced their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Canaccord Genuity Group reduced their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Raymond James reduced their price target on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Finally, Truist Financial set a $101.00 price target on Zimmer Biomet in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and an average price target of $111.53.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.